Saphenous vein graft failure: from pathophysiology to prevention and treatment strategies

I Xenogiannis, M Zenati, DL Bhatt, SV Rao… - Circulation, 2021 - Am Heart Assoc
Saphenous vein grafts (SVGs) remain the most frequently used conduits in coronary artery
bypass graft surgery (CABG). Despite advances in surgical techniques and …

Association of dual antiplatelet therapy with ticagrelor with vein graft failure after coronary artery bypass graft surgery: a systematic review and meta-analysis

S Sandner, B Redfors, DJ Angiolillo, K Audisio… - Jama, 2022 - jamanetwork.com
Importance The role of ticagrelor with or without aspirin after coronary artery bypass graft
surgery remains unclear. Objective To compare the risks of vein graft failure and bleeding …

Antithrombotic treatment strategies in patients with established coronary atherosclerotic disease

M Valgimigli, V Aboyans, D Angiolillo… - European Heart …, 2023 - academic.oup.com
Multiple guidelines and consensus papers have addressed the role of antithrombotic
strategies in patients with established coronary artery disease (CAD). Since evidence and …

Graft failure after coronary artery bypass grafting and its association with patient characteristics and clinical events: a pooled individual patient data analysis of clinical …

M Gaudino, S Sandner, KR An, A Dimagli, A Di Franco… - Circulation, 2023 - Am Heart Assoc
BACKGROUND: Graft patency is the postulated mechanism for the benefits of coronary
artery bypass grafting (CABG). However, systematic graft imaging assessment after CABG is …

Antiplatelet therapy after coronary artery bypass surgery: five year follow-up of randomised DACAB trial

Y Zhu, W Zhang, A Dimagli, L Han, Z Cheng, J Mei… - bmj, 2024 - bmj.com
Objective To assess the effect of different antiplatelet strategies on clinical outcomes after
coronary artery bypass grafting. Design Five year follow-up of randomised Different …

Ticagrelor versus aspirin and vein graft patency after coronary bypass: a randomized trial

A Kulik, AM Abreu, V Boronat… - Journal of Cardiac …, 2022 - Wiley Online Library
Background Antiplatelet therapy prevents saphenous vein graft (SVG) occlusion and
improves outcomes after coronary artery bypass graft surgery (CABG). However, the optimal …

Antithrombotic therapy in patients with established atherosclerotic coronary disease

A Landi, M Valgimigli - Heart, 2023 - heart.bmj.com
Antithrombotic therapy is the cornerstone of the pharmacological treatment in patients with
established coronary artery disease (CAD). 1 Despite technological improvements, the …

[HTML][HTML] Angiographic outcomes for arterial and venous conduits used in CABG

A Dimagli, G Soletti Jr, L Harik… - Journal of Clinical …, 2023 - mdpi.com
Coronary artery bypass grafting is the most commonly performed cardiac surgical
procedure. Conduit selection is crucial to achieving early optimal outcomes, with graft …

Conduit selection and early graft failure in coronary artery bypass surgery: a post hoc analysis of the Cardiovascular Outcomes for People Using Anticoagulation …

M Alboom, A Browne, T Sheth, Z Zheng… - The Journal of Thoracic …, 2023 - Elsevier
Objectives Relative rates of early graft failure and conduit selection in coronary artery
bypass grafting (CABG) surgery remain controversial. Therefore, we sought to determine the …

[HTML][HTML] A Contemporary Review of Antiplatelet Therapies in Current Clinical Practice

S Arockiam, B Staniforth, S Kepreotis… - International Journal of …, 2023 - mdpi.com
Antiplatelet therapy plays a crucial role in a number of cardiovascular disorders. We
currently have a range of antiplatelet agents in our armamentarium. In this review, we aim to …